Skip to main content

Semaglutide's Dual Triumph: Why Novo Nordisk's Type 1 Diabetes Breakthrough Could Ignite Stock Growth

Submitted by admin on
snippet

The diabetes market is on the cusp of a paradigm shift. Novo Nordisk's (NVO) GLP-1 receptor agonist semaglutide, already a blockbuster in type 2 diabetes and obesity, has now shown transformative potential in type 1 diabetes (T1D). A small but groundbreaking study published in 2023 reveals that semaglutide could reduce insulin dependency, improve glycemic control, and drive weight loss in T1D patients using automated insulin delivery (AID) systems. 

Source
AInvest

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

Submitted by admin on
snippet

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. The biotech linked its challenger to bigger reductions in blood sugar than Novo Nordisk’s semaglutide, the ingredient in its obesity and diabetes franchise comprising Wegovy, Ozempic and Rybelsus, giving the company momentum as it barrels toward a readout from a head-to-head trial against Eli Lilly’s tirzepatide.

Source
Fierce Biotech

US court decision stops compounders from making knockoffs of Novo Nordisk's semaglutide

Submitted by admin on
snippet

Makers of knockoff in-demand weight loss drugs are fast running out of options to manufacture them legitimately as a federal court this week dismissed an attempt by compounding pharmacies to continue to produce copycats of Novo Nordisk’s semaglutide while a lawsuit plays out.

Source
Fierce Pharma

Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide

Submitted by admin on
snippet

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global rights to a preclinical prospect that paired well with its GLP-1 blockbuster semaglutide in mice.

Source
Fierce Biotech

Brazil's Hypera to launch an Ozempic generic in 2026, CEO says

Submitted by admin on
snippet

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief executive said on Friday.

Source
MSN/Reuters

Off-label use of semaglutide and tirzepatide shows promise in type 1 diabetes

Submitted by admin on
snippet

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c) levels and body weight among adults with type 1 diabetes (T1D). These findings suggest a potential new therapeutic approach for improving glycemic control and addressing obesity in T1D, an area with few pharmacologic advancements beyond insulin therapy.

Source
Clinical Trials Arena

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

Submitted by admin on
snippet

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity.

In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 mg, which is currently the highest dose of the drug marketed under the Wegovy brand for obesity.

Source
Fierce Pharma

Novo, Viking heat up MASH space with promising data at AASLD24

Submitted by admin on
snippet

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging backbone of MASH treatment, with the potential to combine it with other drug classes to achieve deeper responses, according to BMO Capital Markets analyst Evan Seigerman.

Source
BioSpace

Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO

Submitted by admin on
snippet

Novo Nordisk's CEO told CNN he is "alarmed" by the risks compounded versions of semaglutide — the active ingredient in the company's diabetes drug Ozempic and weight loss drug Wegovy — are posing to users. 

Source
Beckers Hospital Review

Novo, with new results, to seek approval for obesity drug in MASH

Submitted by admin on
snippet

The findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren’t a “silver bullet” for MASH, one analyst argued.

Source
BioPharma Dive